Skip to content

Released May 8, 2020, before the open

10-Q filed May 8, 2020, 38 days after period end · 0001564590-20-023243

Q1 2020 · 10-Q
Revenue$169.00K−95.6% vs Q1 2019−75.7% vs Q4 2019
Net Income-$23.30MN/M vs Q1 2019N/M vs Q4 2019
EPS Diluted-$1.22N/M vs Q1 2019N/M vs Q4 2019
Operating Income-$22,821,000N/M
Operating Cash Flow-$23,329,000N/M
Free Cash Flowderived-$23,408,000N/M
Margins · derived
Operating margin-13503.6%−13353.9 pt vs Q1 2019
Net margin-13787.0%−13653.0 pt vs Q1 2019

What the release said

The release

Same quarter

MetricQ1 2020Q1 2019Q1 2018Q1 2017
Revenue$169.00K$3.81M$1.15M$140.00K
Net Income-$23.30M-$5.10M-$10.64M-$5.88M
EPS Diluted-$1.22-$0.29-$0.74-$21.60

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR